Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.45
    -0.16 (-2.10%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BioCryst Pharmaceuticals Inc (BCRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    BioCryst Pharmaceuticals reported revenue of $874.84M for the fiscal year ended Dec 31, 2025, up 94.1% from the year before. That year, net income was $263.86M with a net margin of 30.2%, operating cash flow was $347.37M and free cash flow was $344.90M. The quarter ended Sep 30, 2026 had revenue of $180.29M and net income of $37.92M.

    Revenue and Margins

    The operating margin was 39.0% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $26.35M, a compound annual rate of 47.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$874.84M+94.1%97.8%39.0%30.2%
    Dec 2024$450.71M+36.0%97.3%-0.6%-19.7%
    Dec 2023$331.41M+22.4%98.6%-31.3%-68.4%
    Dec 2022$270.83M+72.3%97.6%-54.8%-91.2%
    Dec 2021$157.17M+782.4%95.4%-113.1%-117.1%
    Dec 2020$17.81M-63.5%91.3%-981.1%-1026.4%
    Dec 2019$48.84M+136.5%92.4%-203.7%-223.0%
    Dec 2018$20.65M-18.0%100.0%-456.2%-490.3%
    Dec 2017$25.19M-4.4%95.5%-227.9%-261.2%
    Dec 2016$26.35MN/A91.3%-184.4%-209.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 194.0% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$874.84M$450.71M$331.41M$270.83M$157.17M$17.81M$48.84M$20.65M$25.19M$26.35M
    Cost of revenue$19.07M$12.27M$4.48M$6.41M$7.23M$1.55M$3.73M$0$1.14M$2.30M
    Gross profit$855.76M$438.44M$326.93M$264.42M$149.94M$16.26M$45.11M$20.65M$24.04M$24.06M
    Research and development$166.13M$174.64M$216.57M$253.30M$208.81M$122.96M$107.07M$84.89M$66.96M$61.01M
    Operating income$340.99M-$2.54M-$103.71M-$148.44M-$177.72M-$174.76M-$99.45M-$94.22M-$57.41M-$48.61M
    Net income$263.86M-$88.88M-$226.54M-$247.12M-$184.06M-$182.81M-$108.90M-$101.25M-$65.78M-$55.14M
    EBITDA$351.52M-$1.13M-$96.87M-$49.86M-$122.74M-$170.56M-$97.34M-$92.56M-$55.67M-$47.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$180.29M$218.25M$156.41M$406.56M$159.40M$163.35M$145.53M$131.53M$117.08M$109.33M$92.76M$93.40M
    Gross profit$178.72M$214.41M$151.04M$397.03M$157.21M$160.56M$140.97M$125.44M$113.87M$107.63M$91.50M$91.84M
    Operating income$53.33M$98.47M-$701.60M$260.38M$29.59M$29.79M$21.23M-$4.51M$7.69M$8.76M-$14.49M-$42.67M
    Net income$37.92M$78.39M-$721.81M$245.84M$12.90M$5.08M$32.00K-$26.80M-$14.03M-$12.67M-$35.38M-$61.73M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $1.63M by $88.11M. Shareholder equity was negative, at -$119.15M, as total liabilities of $633.31M exceeded total assets of $514.16M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$514.16M$490.42M$516.96M$550.00M$588.15M$334.71M$175.28M$146.84M$178.26M$89.85M
    Current assets$404.35M$421.97M$495.97M$516.50M$566.14M$323.80M$164.34M$114.35M$125.39M$66.99M
    Cash and equivalents$89.74M$104.71M$110.64M$304.77M$504.39M$272.13M$114.17M$26.73M$50.28M$22.10M
    Total liabilities$633.31M$966.35M$972.49M$844.60M$695.14M$353.98M$137.03M$97.61M$94.49M$88.27M
    Short-term debt$1.63M$35.45M$2.65M$2.37M$1.82M$30.00M$38.58M$33.70M$35.22M$28.24M
    Long-term debt$0$314.87M$303.23M$231.62M$136.08M$119.73M$41.29M$25.37M$16.75M$22.78M
    Shareholder equity-$119.15M-$475.93M-$455.53M-$294.60M-$106.99M-$19.26M$38.25M$49.23M$83.77M$1.58M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$591.07M$557.85M$465.05M$514.16M$446.42M$457.19M$480.05M$490.42M$491.25M$472.42M$467.89M$516.96M
    Total liabilities$988.45M$1.01B$1.02B$633.31M$834.31M$878.78M$931.97M$966.35M$959.82M$948.02M$944.06M$972.49M
    Cash and equivalents$96.97M$154.97M$171.59M$89.74M$84.08M$88.03M$105.19M$104.92M$96.84M$78.41M$84.33M$110.64M
    Shareholder equity-$397.38M-$454.29M-$553.84M-$119.15M-$387.89M-$421.59M-$451.93M-$475.93M-$468.56M-$475.61M-$476.17M-$455.53M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.3% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$347.37M-$52.02M-$95.14M-$161.85M-$142.16M-$135.11M-$89.58M-$92.56M-$41.14M-$53.44M
    Capital expenditures$2.47M$1.12M$2.17M$1.35M$2.38M$514.00K$343.00K$366.00K$328.00K$5.28M
    Free cash flow$344.90M-$53.14M-$97.31M-$163.20M-$144.54M-$135.62M-$89.93M-$92.93M-$41.47M-$58.72M
    Investing cash flow-$13.69M$52.59M-$131.50M-$128.24M$15.80M-$6.86M$77.93M$4.77M-$64.64M$23.27M
    Financing cash flow-$349.93M-$5.76M$32.48M$88.03M$359.67M$300.59M$99.10M$62.50M$135.70M$23.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$32.98M$104.34M-$61.79M$291.96M$41.62M$41.30M-$27.52M-$5.21M$8.24M-$1.37M-$53.68M-$8.92M
    Capital expenditures$233.00K$209.00K$403.00K$802.00K$1.34M$179.00K$143.00K$675.00K$59.00K$155.00K$235.00K$554.00K
    Free cash flow$32.75M$104.13M-$62.19M$291.16M$40.28M$41.12M-$27.66M-$5.89M$8.19M-$1.52M-$53.92M-$9.47M
    Last 12 quarters

    Frequently Asked Questions About BCRX

    What is BioCryst Pharmaceuticals' annual revenue?

    BioCryst Pharmaceuticals reported revenue of $874.84M for the fiscal year ended Dec 31, 2025.

    How fast is BioCryst Pharmaceuticals' revenue growing?

    Revenue was up 94.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 47.8%.

    Is BioCryst Pharmaceuticals profitable?

    Yes. BioCryst Pharmaceuticals reported net income of $263.86M for the fiscal year ended Dec 31, 2025, with a net margin of 30.2%.

    How much free cash flow does BCRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $347.37M minus capital expenditures of $2.47M produced free cash flow of $344.90M.

    How much debt does BioCryst Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $1.63M and cash and equivalents of $89.74M.